

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACCORD BIOPHARMA, INC., INTAS PHARMACEUTICALS LTD.,
AND
BIO-THERA SOLUTIONS, LTD.,

Petitioner,

v.

JANSSEN BIOTECH, INC.,

Patent Owner.

IPR2026-00257

Patent No. 11,041,020

DECLARATION OF THAO MARZULLO

I, Thao Marzullo, hereby declare as follows.

1. I am the Director of Customer Experience for the Immunology Portfolio at Johnson and Johnson, and I have personal knowledge of the facts set forth in this declaration. If called as a witness, I could and would testify competently thereto.

2. Janssen Biotech, Inc. (“Janssen”) is sponsor of the Biologics License Application No. 125289 for SIMPONI[®] and Biologics License Application No. 125433 for SIMPONI ARIA[®]. The active ingredient in both SIMPONI[®] and SIMPONI ARIA[®] is golimumab, an antibody that blocks the inflammatory molecule called tumor necrosis factor alpha (TNF α).

3. Janssen is a Pennsylvania corporation with its principal place of business in Horsham, Pennsylvania.

4. I understand that Accord BioPharma, Inc. and Bio-Thera Solutions, Ltd. (together, “Accord”) have submitted an abbreviated Biologics License Application for biosimilar versions of SIMPONI[®] and SIMPONI ARIA[®]. As biosimilars, Accord’s products will directly compete against SIMPONI[®] and SIMPONI ARIA[®].

5. Janssen has spent approximately [REDACTED] to support the marketing and sale of SIMPONI ARIA[®] from 2021-2025.

Declaration of Thao Marzullo

6. Janssen funds patient support programs through J&J withME to help patients access SIMPONI ARIA®. These programs include infusion center locator assistance, co-pay assistance, treatment and education services, and insurance and affordability support. Janssen has invested approximately [REDACTED] from 2021-2025 on such patient support programs for SIMPONI ARIA®.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.



Executed on May 26, 2026, at 5:29 pm ET.